Title

Potential of human Induced Pluripotent Stem Cells in studies of liver disease

Fotios Sampaziotis 1*, Charis-Patricia Segeritz 1*, Ludovic Vallier 1,2.

1 Wellcome Trust Medical Research Council Cambridge Stem Cell Institute, Anne McLaren Laboratory for Regenerative Medicine and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.

2 Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.

* Fotios Sampaziotis and Charis-Patricia Segeritz contributed equally to this work.

Key Words: Disease model, inherited metabolic disorders of the liver, cholangiopathies, cirrhosis, toxicology studies.
Footnote Page

Contact information: Ludovic Vallier, e-mail: lv225@cam.ac.uk

List of abbreviations:

- hIPSC: Human Induced Pluripotent Stem Cells
- HLC: hIPSC-derived hepatocyte-like cells
- CLCs: hIPSC-derived cholangiocyte-like cells
- A1AT: α1-Antitrypsin
- FTA: Familial Transthyretin Amyloidosis
- TTR: Transthyretin
- GSD1a: Glycogen Storage Disease type 1a
- WD: Wilson’s Disease
- FH: Familial Hypercholesterolemia
- HCV: Hepatitis C Virus

Financial support: FS is supported by an Addenbrooke’s Charitable Trust Clinical Research Training Fellowship, a joint Sparks-MRC Clinical Research Training Fellowship and the Cambridge Hospitals National Institute for Health Research Biomedical Research Center. CPS is supported by the Children’s Liver Disease Foundation. LV is supported by the ERC starting grant Relieve IMDs, the Cambridge Hospitals National Institute for Health Research Biomedical Research Center and the EuFp7 grants InnovaLIV and TissuGEN.
Abstract

Liver disease is a leading cause of death in the Western World. However, our insight into the underlying disease mechanisms and development of novel therapeutic agents has been hindered by limited availability of primary tissue, intra-species variability associated with the use of animal models and reduced long-term viability of isolated and diseased liver cells. The emergence of hIPSCs (human Induced Pluripotent Stem Cells) and differentiation protocols to generate hepatocyte-like cells has opened the possibility of addressing these issues. Here we discuss the recent progress and potential in the production of various cell types constituting the liver and their applications to model liver diseases and test drug toxicity in vitro.
Liver disease constitutes a leading cause of death worldwide (1). However, depending on the etiology, treatment options can be limited and liver transplantation remains the only available therapy for end stage liver failure (2). Understanding the disease pathogenesis is crucial for developing new therapeutic agents and diagnostic modalities. Although existing models for the study of hepatic disorders have proven very useful, they also exhibit significant limitations. In vivo models are constrained by intra-species variability (3), while the use of primary tissue is limited by poor availability and technical challenges in culturing primary cells (4). Furthermore, established cell lines are restricted by their malignant background and the requirement for non-physiological manipulations, such as protein overexpression, to replicate the disease phenotype.

Human Induced Pluripotent Stem Cells (hIPSCs) derived from reprogrammed somatic cells (5) demonstrate great potential for overcoming such challenges. Their capacity for self-renewal and differentiation into almost any cell type provides a unique system for generating large quantities of autologous, disease-specific liver cells in vitro. Cells generated through this system constitute an optimal platform for modeling hepatic disorders, provided that they closely resemble their native counterparts, recapitulate key aspects of the disease in question and demonstrate measurable responses to therapeutic agents.

Here, we review how these requirements are addressed by existing culture systems for the generation of hIPSC-derived hepatocytes, describe their applications for modeling hepatic disorders and discuss future directions for the use of hIPSCs in the study of liver disease.

Current approaches for the generation of liver cells from hIPSCs

Given the potential of hIPSCs for modeling hepatic disease, the derivation of different liver cell populations has been the subject of intensive research. Most of these efforts have concentrated on the generation of hepatocytes, which occupy the largest
proportion of the organ volume and are responsible for the majority of its metabolic
functions including detoxification, glucose metabolism, synthesis of plasma proteins
and bile production (6). However, the metabolic activity of hepatocytes is supported
by multiple other cell types collectively known as non-parenchymal liver cells. This
heterogeneous population includes sinusoidal endothelial cells, hepatic stellate cells,
Kupffer cells and cholangiocytes (6). With the exception of cholangiocytes,
differentiation of hiPSCs to non-parenchymal cell types of the liver has not yet been
reported. In this section, we concentrate on current platforms for the generation of
hiPSC-derived hepatocytes and cholangiocytes, their advantages and limitations.

**Hepatocytes**

Primary hepatocytes remain the gold standard for *in vitro* modeling of liver diseases.
However, hiPSC-derived hepatocyte-like-cells (HLCs) could present an excellent
alternative for addressing availability issues, provided they recapitulate key features
of their native counterparts. Indeed, a minimum set of criteria need to be met prior to
characterizing hiPSC-derived cells as ‘hepatocyte-like’. These include expression of
hepatic markers at gene and protein level, demonstration of specific ultrastructural
characteristics, production of albumin, urea and fibrinogen, induction of P450
enzymatic activity following treatment with specific inducers and the use of selected
substrates to confirm phase 1 and 2 metabolic enzyme activity (7-10).

To fulfill these criteria, multiple groups have developed protocols of directed
differentiation towards HLCs (11-16), aimed at recapitulating key stages of natural
liver development including definitive endoderm, foregut, hepatic endoderm,
bipotential hepatoblasts and hepatocyte like cells (17) (Figure 1). All these
approaches converge on the modulation of pathways known to have a pivotal role in
hepatic embryogenesis, such as FGF, BMP4, Wnt, Activin and HGF signaling (17).
The resulting cells bear significant similarities to primary hepatocytes in terms of
transcriptional profile and functional properties, such as albumin and apolipoprotein
B100 (ApoB100) secretion, functional bile transport, LDL uptake, urea synthesis,
cytochrome P450 activity (Cyp3A4) and glycogen storage (16,18). However, HLCs resemble more closely fetal rather than adult hepatocytes, with ongoing expression of fetal markers (AFP) and embryonic P450 activity (Cyp3A7) (Table 1). The fetal identity of HLCs has given rise to a plethora of studies focusing on increasing their functionality. Among these approaches two main strategies emerge: The first concentrates on increasing differentiation efficiency, promoting maturation or enhancing P450 activity and drug metabolism. The use of small molecule compounds (19-20), sequential overexpression of transcription factors controlling various stages of hepatic development (17), direct reprogramming of fibroblasts to induced Hepatic Stem Cells through forced expression of hepatic transcription factors (21-22) and direct reprogramming of fibroblasts to endoderm progenitor cells by combining overexpression of OCT4, SOX2 and Klf4 with small molecule treatment (23) have all been reported to contribute towards achieving this goal. Therefore, it is possible that such methodologies will increasingly complement growth factors driven differentiation of hIPSCs in the future.

The second strategy focuses on accurately simulating the liver microenvironment through 3D culture of HLCs (24), co-culture with endothelial or non-parenchymal cells (25), the use of artificial scaffolds (26) or a combination of these techniques (27). These approaches have also been reported to increase functionality, optimize the transcriptional profile of HLCs and even allow the generation of functional liver organoids with the capacity to engraft in the vasculature of immunodeficient mice (27).

Considered collectively, these advances have contributed towards bridging the gap between primary hepatocytes and HLCs (Figure 1). However, many challenges remain prior to fully achieving this goal, such as the limited capacity of HLCs to repopulate the liver of animal models of hepatic failure. Furthermore, considering the notable differences between primary hepatocytes cultured in vitro and their native counterparts, it is possible that there is a limit to how closely in vitro HLCs can
reproduce the phenotype and function in vivo hepatocytes. Indeed, culture systems maintaining the full functional repertoire of primary hepatocytes are yet to be developed and until then, generation of fully mature hepatocytes in vitro might remain elusive.

**Cholangiocytes**

Cholangiocytes constitute the main cell type affected by diseases of the biliary system, or cholangiopathies. Therefore, differentiation of hIPSCs to cholangiocyte-like cells could provide a novel platform for the study of biliary disorders and the development of new therapeutic agents. The generation of hIPSC-derived cholangiocyte-like cells (CLCs) and organoids has been reported by various groups (28-32). The common denominator in these approaches is the suspension of hepatoblast- or cholangiocyte progenitor-like cells in Matrigel supplemented with EGF, Wnt or HGF. The cells re-organize in 3D polarized structures expressing biliary markers and lacking expression of hepatic markers. The resulting organoids exhibit secretory functionality (28,29,32), alkaline phosphatase (30) and gamma-glutamyl transpeptidase activity (31), as well as responses to hormonal stimuli including somatostatin (32). Despite these advances, the relevance of these approaches to natural development remains vague, which limits their applications for developmental studies and drug screening. Therefore, further optimization of the current culture systems remains a prerequisite for effectively modeling cholangiopathies using hIPSCs.

**Disease models to date**

Since the first proof-of-principle that patient-specific HLCs can be used to model liver diseases (33), the field has expanded rapidly to address a broad range of disorders. Here we review the current hIPSCs-based models for liver disease and their contribution to advancing our insight in the pathophysiology of hepatic disorders (Table 2, Figure 2).
Disease caused by accumulation of misfolded proteins

α1-Antitrypsin (A1AT) Deficiency: A1AT deficiency is an autosomal recessive disorder caused by mutations in the A1AT-encoding SERPINA1 gene (34). A1AT is a protease inhibitor synthesized primarily by hepatocytes. SERPINA1 mutations lead to low levels of serum and alveolar A1AT, which is associated with panlobular emphysema from over-active proteases such as pulmonary neutrophil elastase. Retention of misfolded A1AT polymers within the hepatic endoplasmic reticulum (ER) results in hepatic dysfunction and liver disease (34). A1AT deficiency was the first hepatic disorder to be modelled in vitro using hIPSCs, by differentiating patient-derived hIPSCs into A1AT polymer-retaining HLCs. The disease phenotype was confirmed by ELISA and immunocytochemistry for the polymeric form of A1AT, as well as ER-specific enzyme digests, which indicated entrapment of A1AT in the ER. In a subsequent study, the same group reported rescue of the disease phenotype, following correction of the SERPINA1 mutation using zinc finger nucleases, thereby demonstrating a direct association between the phenotype observed and the underlying genetic defect (35). These results illustrate the potential of hIPSCs for genetic correction, which represents a powerful tool for dissecting the mechanisms of inherited disorders and generating autologous healthy tissue for personalised cell-based therapy.

Familial Transthyretin Amyloidosis (FTA): FTA is a lethal autosomal dominant disease, caused by mutations in the transthyretin-encoding TTR gene, leading to secretion of monomeric misfolded TTR proteins by the liver and formation of extracellular fibrils accumulating as amyloid in target organs, mainly the brain and heart (36). Although the liver participates in the disease pathogenesis through the production of pathological TTR, it does not sustain end organ damage (37). Consequently, in vitro modeling of FTA has been limited by the requirement of multiple cell types to capture the complexity of the disease. These include
hepatocytes for studying the mechanisms controlling TTR production and misfolding, as well as several target cell populations for interrogating the effects of the TTR mutation products.

The capacity of hiPSCs to differentiate towards almost any cell type renders them an ideal platform to overcome this challenge. Indeed, recently Leung et al. reported the generation of hepatocytes, cardiomyocytes and neurons from hiPSCs of patients with FTA (37). Neurons and cardiomyocytes exposed to hepatocyte-secreted mutant TTR, using conditioned media, exhibited oxidative stress and increased cell death. More importantly, the use of small molecules stabilizing TTR exerted a protective effect on the target cell populations (37). Considered collectively, these results illustrate the potential of hiPSCs for modeling diseases affecting several organs simultaneously.

Liver diseases caused by disruption of enzymatic activity

Glycogen Storage Disease type 1a (GSD1a): GSD1a is a rare autosomal recessive disorder caused by mutations in the G6PC-encoded glucose-6-phosphatase (G6PT) (38). G6PT is essential for the regulation of glucose homeostasis through gluconeogenesis and glycogenolysis (38). Consequently, G6PT deficiency manifests with hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia. Lipid and glycogen accumulation in liver and kidneys result in hepatorenomegaly, while growth retardation is also reported. Importantly, glucagon stimulation in these patients increases serum lactate but does not affect serum glucose levels (38). GSD1a has been successfully modelled in vitro using patient-derived HLCs (33). Indeed, GSD1a-HLCs exhibited increased glycogen and lipid accumulation compared to wild-type controls, demonstrated through PAS and BODIPY staining respectively. Furthermore, GSD1a-HLCs showed similar sensitivity to glucagon stimulation compared to wild-type controls; however, lactate synthesis was significantly increased in GSD1a-HLCs. Considered together these experiments
demonstrate the potential of hIPSCs for recapitulating key features of GSD1a in vitro, including glycogen accumulation, hyperlipidemia and lactic acidosis. More importantly, the capacity of HLCs for mimicking the native regulation of glucose and lipid homeostasis, renders them a unique system for studying more complex metabolic liver disorders associated with type 2 diabetes and metabolic syndrome, such as liver steatosis and Non Alcoholic Steatohepatitis (NASH).

**Wilson’s Disease (WD):** WD is an autosomal recessive disorder caused by mutations in the \textit{ATP7B} gene, an ATPase expressed mainly in hepatocytes and mediating hepatocellular excretion of copper in the bile and bloodstream. Hepatic accumulation of copper results in liver damage leading to cirrhosis or in some cases acute liver failure; while increased serum copper levels result in copper deposition and toxicity, affecting multiple organs, mainly the brain, kidneys and cornea (39-40). Current treatments with copper chelators are very effective in reducing copper serum levels; however, liver transplantation remains the only treatment option for acute liver failure and refractory disease (39). Concerning modeling of WD in vitro, 2 groups have generated HLCs from WD patients, exhibiting abnormal cytoplasmic localization of mutant ATP7B and defective copper transport (40-41). More importantly, Zhang et al. reported rescue of the disease phenotype using the chaperone drug curcumin or lentiviral overexpression of wild type \textit{ATP7B}. These results provide proof-of-principle for therapeutic approaches alternative to copper chelators in Wilson’s disease and validate the potential of hIPSC-derived hepatocytes as an appropriate platform for drug validation in the context of this disorder (40).

**Diseases caused by receptor dysfunction**

**Familial hypercholesterolemia (FH):** FH represents the most common and severe form of inherited hypercholesterolemia. The uptake and catabolism of LDL-C in the liver is physiologically mediated by the low density lipoprotein receptor (\textit{LDLR}) on the membrane of hepatocytes. FH is caused by mutations in the \textit{LDLR} inherited in an
autosomal codominant pattern, which result in poor hepatic uptake and high circulating levels of plasma cholesterol levels (LDL-C) irrespective of diet, medications or lifestyle, thereby leading to early onset of cardiovascular disease (42). Furthermore, recent mouse studies suggest a role for LDLR in regulating plasma levels of very low density lipoprotein (VLDL) and ApoB100 (42). However, human data is extremely limited given the difficulties in obtaining primary tissue from FH patients.

HLCs provide an excellent platform for addressing this challenge. Patient-derived HLCs (33,43) exhibit reduced synthesis of LDLR and impaired receptor functionality demonstrated by limited LDL-C uptake in FACS analysis and immunohistochemistry assays (33). The capacity of this system to accurately reproduce the phenotype of different LDLR mutations was demonstrated using a compound heterozygous patient with a non-functional maternal allele and a paternal allele encoding a receptor with physiological binding to LDL-C but defective internalization (43). The resulting HLCs exhibited increased clustering of fluorescently-labelled LDL-C on the cell surface but reduced uptake as a result of impaired endocytosis of LDL-C through the paternally-encoded mutant LDLR. These observations underline the potential of HLCs for dissecting the impact of genetic variations on the disease phenotype. Furthermore, the application of FH-HLCs for drug screening in FH was demonstrated by reproducing the effects of lovastatin, a lipid-lowering agent, known to be ineffective for patients with FH (44). Indeed, FH-HLCs exhibited minimal change in LDL-C uptake compared to wild-type controls, which increased cholesterol uptake appropriately (43). These results provide proof-of-principle for the suitability of FH-HLCs as a platform for testing the efficacy of lipid-lowering agents in the context of FH. Finally, using this culture system, a role for LDLR in regulating ApoB100 levels in human was identified. Indeed, FH-HLCs exhibited an 8-fold increase in secreted ApoB100 compared to wild-type controls, in the absence of enhanced gene expression, suggesting a mechanism involving post-translational degradation of
ApoB100 (43). These results demonstrate the potential of FH-HLCs as a model for studying the molecular pathogenesis of FH.

### Infectious diseases of the liver

**Hepatitis C Virus:** Hepatocytes are susceptible to infection from multiple pathogens including viruses (Hepatitis A–E, CMV, EBV) and parasites (*Plasmodium, Schistosoma*). However, the most common infective cause for liver transplantation is viral infection with Hepatitis C (HCV) (2). Current treatment options for HCV offer only a 50% viral clearance rate, while liver transplantation is complicated by disease recurrence in the graft (2,45). Primary hepatocytes represent the gold standard for studying the pathophysiology of hepatitis C viral infection; however, their limited availability has led to the use of hepatoma lines such as Huh 7.5 (46-47). Although these systems have proven useful for studying the disease, they are limited by inherent differences from primary hepatocytes associated with their cancerous nature, reduced infection efficiency and defects in interferon production. More importantly, cell lines can only be infected by specific HCV genotypes and are resistant to infection with human sera (47). HLCs provide an alternative platform for the study of HCV that addresses some of these challenges. In particular, they express the necessary receptors for the entry of HCV in the cells (47-49), support the full life cycle of the virus (50) and reproduce key inflammatory responses to infection, including TNFα and interleukin 28 secretion (47,50). In contrast to hepatoma lines, HLCs can be infected using infected patient sera (47,49). Interestingly, using HLCs, Wu et al. have identified key factors regulating permissiveness to viral infection including the upregulation of micro-RNA 122 and suppression of antiviral genes such as interferon-induced transmembrane protein-1 (47). Most importantly, the same group generated genetically modified hepatocytes resistant to HCV infection, thereby addressing a major challenge for liver transplantation and autologous cell therapy in HCV patients; preventing recurrence of the disease in the transplanted tissue (2,47).
Considered collectively, these studies demonstrate the potential of hIPSCs for modeling host-pathogen interactions in infectious hepatic disorders and constitute the first example of HLCs used in the study of a non-genetic liver disease. Importantly, a similar approach could be applied for the study of other common liver pathogens, including HBV (51) or parasitic infections (52).

The potential of hIPSCs for modeling complex liver disease

With the exception of HCV, all liver diseases modeled to date using hIPSCs constitute rare monogenic metabolic disorders that collectively account for less than 10% of the total number of liver transplants performed (2) (Table 2). Therefore, a major challenge for regenerative medicine in hepatology is evolving from proof-of-principle models to modeling more complex disorders that constitute leading causes for chronic liver disease and transplantation.

Modeling cirrhosis: Hepatic failure secondary to cirrhosis constitutes the endpoint in the natural history of the majority of chronic liver disorders and one of the most common causes of death in the Western world (2). It is caused by disruption of the liver architecture due to excessive deposition of connective tissue by hepatic stellate cells (53). However multiple other cell types contribute to the disease through activating stellate cells or triggering inflammatory responses. These include hepatocytes, Kupffer cells and sinusoidal endothelial cells (53). One of the major difficulties in modeling cirrhosis in vitro is accurately reproducing these intricate cellular interactions controlling the disease pathogenesis. To overcome this challenge various approaches have been used. In vivo models based on administration of toxic compounds, Schistosoma infection or bile duct ligation to induce cirrhosis have proven useful; however they are not specific to the underlying liver disease and they are limited by intra-species variability (54). In vitro models based on 3D platforms enabling co-culture of primary hepatocytes and stellate cells (53) address some of these issues; however, they are also restricted by poor access
to primary tissue. The use of hIPSCs-based platforms simulating the liver microenvironment could contribute towards overcoming these limitations. Indeed, introduction of stellate and Kupffer cells in existing organoid culture systems combining HLCs, endothelial and stromal cell populations (25,27) could provide an excellent model for studying the cellular interactions controlling the pathogenesis of cirrhosis. In the absence of protocols for the generation of hIPSC-derived stellate cells, stellate cell lines could be used, while macrophages acting as Kupffer cells could be derived from hIPSCs or isolated from peripheral blood. Finally, the most challenging aspect might not be to source all the cells necessary to mimic the liver environment but to reproduce chronic hepatocyte injury in vitro. Indeed, cirrhosis/fibrosis secondary to certain etiologies, such as congestive cardiac failure can prove challenging to model especially in a culture system with a short half-life (10). Furthermore, the impact of the fetal phenotype of HLCs for such platforms remains unclear. To conclude, multicellular organoid platforms based on HLCs could provide one of the most accurate systems to date for reproducing the complexity of cirrhotic tissue in vitro. However, several challenges remain to be addressed, which will require major advances in 3D co-culture systems.

Modeling biliary disease: Bile duct disorders constitute an important cause for chronic liver disease and transplantation (2). However, treatment options are extremely limited (2) and our understanding of the disease pathogenesis is restricted by lack of appropriate disease models. Indeed, in vivo models fail to fully recapitulate the disease phenotype, while primary cholangiocytes are extremely difficult to culture in vitro (55). CLCs could contribute towards addressing this challenge. Culture systems recapitulating key stages of native biliary differentiation and tubulogenesis could increase our insight into the mechanisms of bile duct specification and provide an ideal platform for modeling infantile cholangiopathies caused by defects in biliary tree development (56). Furthermore, patient-derived CLCs represent an excellent
system for interrogating the impact of genetic modifiers in the pathogenesis of complex biliary disorders, such as Primary Biliary Cirrhosis (PBC). Recent genome-wide association studies have identified multiple loci associated with PBC (57), but their expression and function in cholangiocytes remains largely unknown. CLCs could address this challenge by delivering an in vitro platform with the capacity to characterize which of these loci are expressed in biliary tissue and enable further studies on their function and mechanism of action.

Modeling hepatotoxicity and Drug Induced Liver Injury

Hepatotoxicity constitutes the second most common cause for drug failure in human (58), while Drug Induced Liver Injury (DILI) accounts for 50% of acute liver failure cases (59). The mechanisms controlling drug sensitivity and idiosyncratic reactions remain largely unknown. Genetic factors are considered to play a major role; however limited access to primary tissue precludes the development of large scale in vitro platforms capturing the genetic diversity of a population and allowing in-depth genomic studies. HLCs could overcome this limitation by providing large numbers of isogenic cells capable of reproducing the effects of various therapeutic compounds in vitro. However, the differences in drug metabolism between primary hepatocytes and HLCs remain a significant limitation that needs to be assessed and addressed in order to maximize the potential of HLC-based platforms for modeling hepatotoxicity and DILI. The development of new protocols (16,20,24) could provide novel perspectives towards achieving this goal. Furthermore, the recent development of extensive hiPSC libraries such as the HipSci project (http://www.hipsci.org/), combined with advances in automated cell culture and high throughput techniques (60-61), provide an excellent infrastructure for deriving substantial cohorts of HLCs reproducing the genetic variability and polymorphisms accounting of drug toxicity. High-throughput sequencing and phenotyping platforms could enable direct comparison of the genetic profiles between HLC cohorts derived from healthy
individuals and patients with DILI or hypersensitivity reactions in order to identify
novel genetic variants associated with hepatotoxicity. HLCs expressing these
variants could subsequently be used to interrogate the mechanisms controlling drug
toxicity and provide more accurate screening platforms for early identification of toxic
compounds.

Conclusion

In conclusion, recent technical advances in differentiation protocols combined with
the development of complex organoid culture systems have significantly improved
the quality and spectrum of hIPSC-derived liver cell types. As a result hIPSC-based
liver disease modeling is rapidly expanding from reproducing key phenotypic aspects
of rare monogenic disorders to modeling diseases representing major causes for
chronic liver disease and transplantation, such as HCV. In addition, novel
technologies becoming rapidly available in the field will enable studies at the deepest
molecular level, linking genetics, epigenetics and phenotype in the context of
complex liver disorders; thereby pushing the boundaries of regenerative hepatology
even further in the near future.

Conflict of interest

LV is a founder and shareholder of Definigen. The rest of the authors have nothing to
disclose.
References


efficient generation of human hepatocyte-like cells from induced pluripotent

13. Touboul T, Hannan NR, Corbineau S, Martinez A, Martinet C, Branchereau S,
et al. Generation of functional hepatocytes from human embryonic stem cells
under chemically defined conditions that recapitulate liver development.

14. Hannan NR, Segeritz CP, Touboul T, Vallier L. Production of hepatocyte-like

drug metabolic function induced from fibroblasts by lineage reprogramming.

al. Three-dimensional culture and cAMP signaling promote the maturation of

17. Si-Tayeb K, Lemaigre FP, Duncan SA. Organogenesis and development of

al. Efficient generation of functional hepatocytes from human embryonic stem
cells and induced pluripotent stem cells by HNF4α transduction. Mol Ther.

Identification of small molecules for human hepatocyte expansion and iPS

Identification of small molecules for human hepatocyte expansion and iPS


Pediatr. 2002;161:S20-S34.


Figure Legends

Figure 1
Strategies the generation of Hepatocyte-Like-Cells (HLCs) from human Induced Pluripotent Stem Cells (hIPSCs). Key stages of *in vivo* liver development are compared to *in vitro* differentiation of HLCs and the growth factors controlling each stage are mentioned. Approaches for improving HLC maturation are also summarized.

Figure 2
Liver disease pathways modeled with patient-specific hIPSC-derived hepatocytes. The underlying pathophysiology of several hepatic disorders modeled in hIPSC-derived hepatocytes is outlined (red) and shown to deviate from the WT phenotype (green). (1) **α1-Antitrypsin Deficiency**: Accumulation of misfolded α1-antitrypsin in the ER. (2) **Familial Transthyretin Amyloidosis**: Secretion of misfolded protein and formation of extracellular fibrils. (3) **Glycogen Storage Disease Type 1a**: Disruption of enzymatic activity. (4) **Familial Hypercholesterolemia**: Cell membrane receptor dysfunction. (5) **Hepatitis C Virus**: Permissiveness of viral infection and replication.
Table Legends

Table 1

Key characteristics of HLCs generated in vitro including expression of liver specific markers, in vivo engraftment potential and functionality in comparison to primary hepatocytes.

Table 2

Contribution of hPSCs to modeling liver disease. Key hepatic disorders leading to liver transplantation and relevant hPSC-based models currently available.
<table>
<thead>
<tr>
<th>Protocol / Publication</th>
<th>Positive Control</th>
<th>Hepatic Markers</th>
<th>Hepatic Functional Assays</th>
<th>Murine Engraftment $\textit{in vivo}$</th>
<th>Disease Modeling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Du et al. Cell Stem Cell 2014</td>
<td>freshly isolated human primary hepatocytes</td>
<td>ALB AAT AFP negative HNF4A CYP3A4</td>
<td>$\sim 80$-$270%$  $\sim 60%$ yes yes yes yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogawa et al. Development 2013</td>
<td>freshly isolated, cryopreserved human primary hepatocytes</td>
<td>ALB AAT AFP HNF4A CYP3A4</td>
<td>$\sim 900%$ *  $\sim 1400%$ * n/a n/a yes n/a n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Si-Tayeb et al. Hepatology 2010</td>
<td>cadaveric human liver samples</td>
<td>ALB AFP HNF4A CYP3A4</td>
<td>n/a n/a yes yes yes yes yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hay et al. PNAS 2008</td>
<td>primary adult human hepatocytes</td>
<td>ALB AFP HNF4A CYP3A4</td>
<td>n/a n/a yes n/a n/a yes yes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* CYP3A4 activity and albumin secretion in HLCs were compared to those of cryopreserved plated hepatocytes, explaining the level observed.
<table>
<thead>
<tr>
<th>Etiology</th>
<th>% of liver transplantations</th>
<th>hIPSC-based models</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cirrhosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral (HBV, HCV)</td>
<td>24%</td>
<td>1. Wu X, et al. (40)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Roelandt P, et al. (41)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3. Yoshida T, et al. (42)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4. Schwartz RE, et al. (43)</td>
</tr>
<tr>
<td>Alcohol</td>
<td>19%</td>
<td>None available</td>
</tr>
<tr>
<td>Alcohol + virus</td>
<td>3%</td>
<td>None available</td>
</tr>
<tr>
<td>Primary Biliary Cirrhosis (PBC)</td>
<td>6%</td>
<td>None available</td>
</tr>
<tr>
<td>Autoimmune</td>
<td>2%</td>
<td>None available</td>
</tr>
<tr>
<td>Secondary Biliary Cirrhosis</td>
<td>1%</td>
<td>None available</td>
</tr>
<tr>
<td>Cancer</td>
<td>14%</td>
<td>None available</td>
</tr>
<tr>
<td>Cholestatic diseases</td>
<td>10%</td>
<td>None available</td>
</tr>
<tr>
<td>Acute Hepatic Failure</td>
<td>8%</td>
<td>None available</td>
</tr>
<tr>
<td>Metabolic diseases</td>
<td>6%</td>
<td>Rashid ST, et al. (26)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yusa K, et al. (28)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rake JP, et al. (31)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zhang S, et al. (33)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yi F, et al. (34)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cayo MA et al. (36)</td>
</tr>
<tr>
<td>Other (Budd Chiari, benign liver tumors, polycystic disease)</td>
<td>3%</td>
<td>Leung A, et al. (30)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Klotz C et al. (45)</td>
</tr>
</tbody>
</table>